Abivax Announces Positive Results for Obefazimod in Ulcerative Colitis Treatment

Abivax has shared positive interim results for their open-label maintenance study of obefazimod, a treatment for moderate to severe ulcerative colitis. Patients administered a reduced 25 mg dose daily showed high rates of clinical remission after 48 and 96 weeks. At baseline, 89% of patients were in remission, with 84% maintained at week 48, and 87% at week 96.

Safety results aligned with previous studies, showing no new safety concerns. Patient retention was strong, with minimal discontinuation. These findings support obefazimod as a promising long-term therapy for ulcerative colitis.

Obefazimod's oral administration offers a convenient option, meeting a significant need in ulcerative colitis treatment. Further data will be presented at an upcoming medical meeting.